Dragonfly Therapeutics, BMS agree to exclusive global license for IL-12 investigational immunotherapy program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Dragonfly Therapeutics Inc. and Bristol Myers Squibb have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 investigational immunotherapy program, including its extended half-life cytokine DF6002.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login